Ocugen (OCGN) Shares Outstanding (Weighted Average) (2014 - 2026)
Ocugen posted quarterly Shares Outstanding (Weighted Average) of $327.5 million for Q1 2026, up 12.17% year-on-year from $292.0 million in Q1 2025, and up 1490.02% on a QoQ basis from $20.6 million in Q4 2025.
Ocugen (OCGN) has 13 years of Shares Outstanding (Weighted Average) data on file, last reported at $327.5 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 12.17% year-over-year to $327.5 million; the trailing twelve-month figure through Mar 2026 stood at $327.5 million (up 12.17% YoY), and the FY2025 full-year result was $300.2 million, up 10.77% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $327.5 million, up from $20.6 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $327.5 million in Q1 2026 and bottomed at $20.6 million in Q4 2025.
- The 5-year median for Shares Outstanding (Weighted Average) is $244.3 million (2023), against an average of $239.7 million.
- The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) rose 14.06%; it then plunged 92.4% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $214.6 million in 2022, then grew by 13.85% to $244.3 million in 2023, then increased by 10.91% to $271.0 million in 2024, then slumped by 92.4% to $20.6 million in 2025, then jumped by 1490.02% to $327.5 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $327.5 million (Q1 2026), $20.6 million (Q4 2025), and $296.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | 327.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 327.54 Mn |
| Dec 31, 2025 | 20.60 Mn |
| Sep 30, 2025 | 296.07 Mn |
| Jun 30, 2025 | 292.07 Mn |
| Mar 31, 2025 | 292.00 Mn |
| Dec 31, 2024 | 271.00 Mn |
| Sep 30, 2024 | 278.17 Mn |
| Mar 31, 2024 | 257.23 Mn |
| Dec 31, 2023 | 244.33 Mn |
| Jun 30, 2023 | 238.31 Mn |
| Mar 31, 2023 | 225.52 Mn |
| Dec 31, 2022 | 214.60 Mn |
| Sep 30, 2022 | 216.59 Mn |
| Jun 30, 2022 | 215.86 Mn |
| Mar 31, 2022 | 205.69 Mn |
| Dec 31, 2021 | 195.01 Mn |
| Sep 30, 2021 | 198.79 Mn |
| Jun 30, 2021 | 190.96 Mn |
| Mar 31, 2021 | 186.30 Mn |
| Dec 31, 2020 | 112.24 Mn |
| Sep 30, 2020 | 92.76 Mn |
| Jun 30, 2020 | 83.54 Mn |
| Mar 31, 2020 | 1,000.00 |
| Dec 31, 2019 | 13.89 Mn |
| Sep 30, 2019 | 5.84 Mn |
| Jun 30, 2019 | 6.07 Mn |
| Mar 31, 2019 | 4.96 Mn |
| Dec 31, 2018 | 4.96 Mn |
| Sep 30, 2018 | 4.96 Mn |
| Jun 30, 2018 | 28.21 Bn |
| Mar 31, 2018 | 27.67 Bn |
| Dec 31, 2017 | 22.67 Mn |
| Sep 30, 2017 | 22.22 Mn |
| Jun 30, 2017 | 22.18 Mn |
| Mar 31, 2017 | 21.91 Mn |
| Dec 31, 2016 | 14.26 Mn |
| Sep 30, 2016 | 13.30 Mn |
| Jun 30, 2016 | 13.27 Mn |
| Mar 31, 2016 | 13.27 Mn |
| Dec 31, 2015 | 13.23 Mn |
| Sep 30, 2015 | 13.22 Mn |
| Mar 31, 2015 | 13.20 Mn |
| Dec 31, 2014 | 1.53 Mn |
| Sep 30, 2014 | 598,684.00 |
| Jun 30, 2014 | 588,936.00 |
| Mar 31, 2014 | 582,246.00 |